secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lakewood-Amedex Biotherapeutics Inc. (LABT)
CIK:        0002079272
Form:       8-K
Filed at:   2026-11-10T22:20:52+00:00
Accession:  0001213900-26-118127
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Lakewood-Amedex redeems all 127,097 Series C preferred shares for $1.27M cash
-----------------------------------------------------------------------------

- Redeemed 127,097 Series C Convertible Preferred shares at $10.00 face value, aggregate $1,270,970 paid in cash from cash on hand.
- Redemption agreement dated Nov 2, 2026 with Shakawe Capital LLC, holder of all Series C preferred; closing occurred Nov 4, 2026.
- Following redemption, no preferred stock and no outstanding indebtedness for borrowed money remain; redeemed shares returned to treasury.
- Company says the move eliminates potential dilution from Series C conversion and removes financing restrictions tied to the instrument.
- CEO Kelvin Cooper said the redemption simplifies the capital structure and gives greater financial flexibility for development programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026118127/0001213900-26-118127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2079272/000121390026118127/ea0311576-8k_lakewood.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-118127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer